.jpg)
13 hours ago
1
Article content
- Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery
- Preclinical data demonstrates sustained efficacy and safety for six months or more following a single injection
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) — Optigo Biotherapeutics, a biotechnology company pioneering long-acting, bi-functional intravitreal biologics, today announced that it has been awarded the People’s Choice Award at Eyecelerator 2025 in Park City, Utah.
Article content
Article content
Concurrently, the company presented positive preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, supporting the potential of its proprietary anti-VEGF molecules to achieve dosing intervals of six months or longer in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Our bi-functional intravitreal biologics are designed to fundamentally address the limitations of current anti-VEGF therapies by dramatically reducing the dosing frequency,” said Houman Hemmati, MD, PhD, Chief Medical Officer and Co-founder of Optigo Bio. “The recognition from industry peers at Eyecelerator, along with the compelling preclinical data we shared at ARVO, underscore both the innovation and real-world potential of our platform.”
Article content
The company’s proprietary biologics are fusion proteins that combine derisked therapeutics such as aflibercept with an albumin or hyaluronan anchoring domain. In VEGF challenge animal models, these bifunctional molecules demonstrate 2-3x longer half-life compared to aflibercept alone, were not proinflammatory, and were well tolerated with a favorable safety profile.
Article content
Article content
Dr. David Boyer, retina specialist at Retina Vitreous Associates Medical Group, commented: “I’m particularly excited about the data Optigo Bio presented at ARVO. The favorable preclinical safety profile combined with their anchoring technology, which enhances half-life and efficacy, represents a promising new treatment option for patients with nAMD and other retinal neovascular diseases.”
Article content
Optigo’s Eyecelerator presentation— “Developing Breakthrough Therapies to Restore Vision”—was delivered by Dr. Hemmati during the Retina TKI and Drug Delivery Showcase and was well-received by attendees for its bold, yet evidence-backed approach to solving one of the biggest challenges of chronic intravitreal therapy.
Article content
Ali Ardakani, CEO and Co-founder of Optigo Bio, added: “While anti-VEGF therapies have significantly reduced blindness globally, real-world outcomes are limited by the burdensome injection schedule. Our platform addresses this bottleneck directly by offering biologics that deliver real efficacy with fewer injections.”
Article content
Optigo’s technology is well-positioned to capture a significant portion of the growing $14B anti-VEGF market by improving patient adherence and outcomes.
English (US)